Drug Profile
S 7 - Transition Therapeutics
Latest Information Update: 15 Mar 2006
Price :
$50
*
At a glance
- Originator Transition Therapeutics
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 15 Mar 2006 No development reported - Preclinical for Multiple sclerosis in Canada (unspecified route)
- 24 Sep 2002 Preclinical trials in Multiple sclerosis in Canada (unspecified route)